The Antidiabetic PPARggr Ligands: An Update on Compounds in Development

Authors: Leff T.; Reed J.E.

Source: Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents, Volume 2, Number 1, March 2002 , pp. 33-47(17)

Publisher: Bentham Science Publishers

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

A novel class of antidiabetic agents, the thiazolidinediones, was developed in the 70s and 80s by screening newly synthesized compounds for their ability to lower blood glucose in diabetic rodents. Three molecules from this class, troglitazone, rosiglitazone and pioglitazone, were ultimately approved for the treatment of patients with type II diabetes. Although these compounds were developed without an understanding of their molecular mechanism of action, by the early 90s evidence began to accumulate linking the thiazolidinediones the nuclear receptor PPARggr (NR1C3). It was ultimately demonstrated that these molecules were high affinity ligands of PPARggr and that they increased the transcriptional activity of the receptor. Although many questions remain, multiple lines of evidence now indicate that the antidiabetic activities of the thiazolidinediones are mediated by their direct interaction with the receptor and the subsequent modulation of PPARggr target gene expression. The knowledge that PPARggr ligands can improve insulin resistance in diabetics, coupled with the availability of rapid assays for the identification and characterization of nuclear receptor ligands, has led to a virtual explosion in the number of new PPARggr ligands that are under development as antidiabetic agents. In this article we will briefly review the biology of PPARggr, and then provide an update of new synthetic PPARggr ligands that are under investigation or in development as antidiabetic drugs.

Keywords: antidiabetic; transcription; troglitazone; roziglitazone; pioglitazone; diabetes

Language: English

Document Type: Review article

DOI: 10.2174/1568013024606440

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A